High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
ImmunityBio (IBRX) delivered earnings and revenue surprises of +11.11% and +5.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Investors are also watching for partnership or buyout catalysts as ImmunityBio expands Anktiva internationally and builds its global NK-cell platform.
ImmunityBio (IBRX) delivered earnings and revenue surprises of -12.50% and +7.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
IBRX's Q1 outlook rides on Anktiva's surging uptake, with preliminary revenues showing triple-digit growth ahead of its earnings report later this month.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.